60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6

60 Degrees Pharma shares are trading lower after the company announced its plans to conclude enrollment in its severe babesiosis study at 30 patients and unblind the trial, with final results expected in January 2027.

60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blindedAs of the

60 Degrees Pharmaceuticals To Present Data On Interim Analysis From Its Clinical Trial Of Tafenoquine On Oct. 6

60 Degrees Pharmaceuticals Says It Submitted Statement Of Interest To FDA For Commissioner's National Priority Voucher For ARAKODA In Babesiosis; DSMB Interim Analysis Of Phase 2 Trial Scheduled October 1, Targets sNDA Submission In March-April 2027

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001946563/000121390026099702/ea0305442-8k_60degree.htm